论文部分内容阅读
目的:总结急性心肌梗塞尿激酶治疗方式,探讨尿激酶治疗心肌梗塞效果;方法:将2012年04月-2013年05月492例急性心肌梗塞患者随机平均分配成两组,即溶栓组和对照组,溶栓组行尿激酶(WK)治疗,对照组行常规性一般治疗,两种治疗方式采用创伤性与非创伤性冠脉再通指标对比观察治疗心肌梗塞效果;结果:溶栓组冠脉再通患者共244例(再通率为99.19%),明显高于对照组再通患者144例(再通率为58.54%),具有显著统计学对比意义(P<0.05);溶栓组近期死亡率0.81%,明显低于对照组死亡率6.1%,具有显著统计学意义(P<0.05);溶栓组胸痛缓解即发病平均时间为1.22h,对照组平均时间见为5.4h,具有显著统计学意义(P<0.05)。结论:尿激酶溶栓治疗急性心肌梗塞疗效显著,值得在以后急性心肌梗塞临床治疗中推广应用;
Objective: To summarize the treatment of acute urokinase in patients with acute myocardial infarction and explore the effect of urokinase in the treatment of myocardial infarction.Methods: 492 patients with acute myocardial infarction from April 2012 to May 2013 were equally divided into two groups randomly: the thrombolytic group and the control group Group and thrombolytic group were treated with urokinase (WK). The control group received routine general treatment. The two treatment methods were compared with traumatic and non-traumatic coronary recanalization indicators to observe the effect of myocardial infarction. Results: A total of 244 patients with recanalization (recanalization rate was 99.19%) were significantly higher than those in control group (144 cases, recanalization rate was 58.54%), with significant statistical significance (P <0.05) The recent mortality was 0.81%, which was significantly lower than that of the control group (6.1%) (P <0.05). The mean time to relieve chest pain in thrombolysis group was 1.22 hours, and the average time in control group was 5.4 hours Significant statistical significance (P <0.05). Conclusion: Urokinase thrombolytic therapy for acute myocardial infarction has significant curative effect, which is worthy of promotion and application in the future clinical treatment of acute myocardial infarction.